(R)-4-Isopropyl-2-(1,8-naphthyridin-2-yl)-4,5-dihydrooxazole, 97%, 100mg

Natriumazid, min. 99 %, p.a., 500 g, kunststoffverpackung.

1-[4-(pyridin-2-yloxy)phenyl]methanamine dihydrochloride, 95.0%, 250mg

1-(2-CHLOROPYRIDIN-4-YL)CYCLOPROPANECARBOXYLIC ACID, 95.0%, 100mg

4-Trifluoromethyl-5,6,7,8-tetrahydroquinazolin-2-ylamine, 95.0%, 100mg

Propionsäureanhydrid, min. 98,5 %, zur Synthese, 100 ml, Glasverpackung

4-[(4-methyl-2-pyridinyl)amino]-4-oxobutanoic acid, 95.0%, 5g

3-Methylquinoxaline-5-carboxylic acid, 98.0%, 1g

Thalidomide-O-C4-COOH, 1g

(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpent-4-enoic acid, 95.0%, 1g

1-Octyl-1H-imidazole, 95.0%, 10g

4'-Trifluoromethylbiphenyl-4-carboxylic acid, 95.0%, 1g

8-Bromoquinolin-3-ol, 98%, 1g